Melanoma is the deadliest form of skin cancer that develops from melanocytes, a pigment-producing cell. The incidence of melanoma has doubled over the last three decades in the United States (1). With treatment, the five-year survival rate is more than 90% for cases contained at the primary site, and less than 30% once there is metastasis. Early detection is therefore crucial to prevent local invasion and distant spread.

See All Related Antibodies

 

 

S100B, a member of the S100 family of calcium-binding cytosolic proteins, is an independent prognostic marker for melanoma (2-4). Elevated S100B and lactate dehydrogenase (LDH) levels are clinically useful for the detection of tumor progression and metastasis (5). GeneTex’s S100 beta antibody (GTX129573) is a well-cited antibody validated for western blot, immunohistochemistry, and immunostaining in various species, including human, mouse, and rat (Figure 1).

Figure 1. GeneTex’s S100 beta antibody (GTX129573) detects S100B protein in mouse retina by immunohistochemistry (green) and by western blot in A375 cell lysates.

 

LDHA facilitates glycolytic flux by converting pyruvate to lactate and NADH to NAD+. It is primarily cytoplasmic, but is also found in mitochondria and the nucleus. In addition to its metabolic function, LDHA is also a single‐stranded DNA‐binding protein participating in DNA duplication and transcription. Elevated expression of LDHA is observed in various cancers. In melanoma, LDHA regulates mitochondrial ROS accumulation, tropomyosin oxidation, and cytoskeletal remodeling to control tumor metastasis. Blockade of LDHA resulted in improved efficacy of PD-1/PD-L1-related immunotherapy (6). GeneTex’s LDHA antibody (GTX101416) is a well-cited polyclonal antibody validated for multiple applications and species (Figure 2).

Figure 2. GeneTex’s LDHA antibody (GTX101416) exhibits an expected staining pattern in ICC/IF and generates a robust band at the predicted molecular weight in various human cell lines by western blot.

 

Melan A, also known as MART1, is a melanocyte lineage-specific marker. The mouse monoclonal antibody [A103] was raised against recombinant Melan A and is positive in most primary melanomas as well as being a useful tool to detect metastatic disease [7]. Melanoma-associated Antigen is recognized by the mouse monoclonal antibody [HMB-45], which is positive in 90-100% of primary melanomas (Figure 3).

Figure 3. GeneTex’s Melan A antibody [A103] (GTX34832) detects MelanA protein by immunohistochemistry in human melanoma tissue (left), while the Melanoma-associated Antigen antibody [HMB-45] (GTX71957) is another valuable marker for both primary and metastatic melanomas (right).

 

Table: Markers associated with Melanoma

Product Name Reactivity Applications Cat. No. S100 beta antibody Hu, Ms, Rat, Squirrel WB, ICC/IF, IHC-P, IHC-Fr GTX129573 LDHA antibody Hu, Ms, Rat WB, ICC/IF, IHC-P GTX101416 Melan A antibody [A103] Hu, Ms, Rat, Dog WB, ICC/IF, IHC-P, FACS GTX34832 Melanoma associated antigen antibody [HMB45] Hu WB, ICC/IF, IHC-P GTX71957 Melanoma gp100 antibody [PMEL/2037] Hu IHC-P, ELISA, Protein Array GTX17772 MITF antibody Hu, Ms, Chk, Xenopus WB, ICC/IF, IHC-P, IHC-Fr, ChIP assay GTX00738

 

References:

1. "SEER Stat Fact Sheets: Melanoma of the Skin".
2. Oncology. 2005;68(4-6):341-9.
3. Tumori. Nov-Dec 2004;90(6):607-10.
4. J Clin Oncol. 2009 Jan 1; 27(1): 38–44.
5. Pathol Oncol Res. 2002;8(3):183-7.
6. Cancers (Basel). 2019 Apr; 11(4): 450.
7. Am J Clin Pathol. 2002 Dec;118(6):930-6.